Afinitor (everolimus) ( DrugBank: Everolimus )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 137 | Focal cortical dysplasia | 1 |
137. Focal cortical dysplasia
Clinical trials : 9 / Drugs : 5 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 51
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03198949 (ClinicalTrials.gov) | May 24, 2018 | 13/6/2017 | A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | Epilepsy and Focal Cortical Dysplasia II | Drug: Afinitor (everolimus) | Yonsei University | NULL | Completed | 4 Years | 40 Years | All | 23 | Phase 2 | Korea, Republic of |